Manages OA 1.2 Rheumatoid Arthritis (RA). ANDA 211412, held by Pharmobedient. Celecoxib.
As of Nov 15, 2026, ANDA 211412 (Celecoxib), held by Pharmobedient, was first approved by FDA on Mar 6, 2020, with 2 approved supplements and 0 published complete response letters.
1. INDICATIONS AND USAGE Celecoxib capsules are indicated Celecoxib capsule is a nonsteroidal anti-inflammatory drug indicated for: Osteoarthritis (OA) Rheumatoid Arthritis (RA) Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older Ankylosing Spondylitis (AS) Acute Pain (AP) Primary Dysmenorrhea (PD) 1.1 Osteoarthritis (OA) For the management of the signs and symptoms of OA 1.2 Rheumatoid Arthritis (RA) For the management of the signs and symptoms of RA 1.3 Juvenile Rheumatoid Arthritis (JRA) For the management of the signs and symptoms of JRA in patients 2 years and older 1.4 Ankylosing Spondylitis (AS) For the management of the signs and symptoms of AS 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 6, 2020 | Original application | Approved | None posted |
| Oct 15, 2025 | Supplement 1Labeling · Standard review | Approved | None posted |
| Oct 15, 2025 | Supplement 8Labeling · Standard review | Approved | None posted |
| Mar 6, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters